Reveals that AAA point-prescription underestimates dose in limited-stage small-cell lung cancer, suggesting alternative calculations.
The AAA point-prescription approach can systematically underestimate target dose in 3D conformal radiotherapy for limited-stage small-cell lung cancer and shows less robust dose-volume behavior across GTV, CTV, and PTV compared with volume-based prescription and Boltzmann transport calculations. Therefore, AAA with point prescription should be avoided for dose calculation in this setting.
No takes yet. Share an insight, caveat, or question.
Okada et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: